KKR buyout agreement defines the near-term future
- Integer is a medical device outsource manufacturer, meaning it builds parts and finished devices for OEM customers.
- The company agreed to be acquired by KKR for $127 per share in cash, concluding its strategic review.
- The bull case relies on the merger closing, which removes the risk of standalone operations.
- If the deal fails, the stock will trade on a weaker outlook tied to slower electrophysiology product adoption.
- Full-year 2026 guidance was previously cut, highlighting the stakes if the transaction does not happen.
A definitive agreement caps the story
Integer has entered into a definitive agreement to be acquired by KKR for $127 per share in cash. This successful conclusion to the strategic review process shifts the narrative entirely. The stock is now a merger arbitrage play, focused on the likelihood and timing of the deal closing.
The bull case is straightforward. The KKR acquisition removes all standalone execution risk and delivers a premium cash exit for shareholders. If regulatory clearances and shareholder approvals proceed normally, investors simply wait for the cash payout.
The bear case centers on the deal breaking. If the merger fails to close by the outside date of May 2, 2027, the stock will be forced to trade on standalone fundamentals. Those fundamentals are currently pressured by lower than expected market adoption for new products in the electrophysiology and neuromodulation markets, which led to a guidance cut earlier in 2026.
Finn's view reflects this binary outcome. The company has valuable, sticky manufacturing relationships, but near-term operational headwinds mean that a failed deal would likely result in a harsh reset to lower valuation multiples.
Sticky work for medtech OEMs
Integer makes money by designing and manufacturing medical device components and, in some cases, complete devices. Its customers are original equipment manufacturers, or OEMs, which sell the final products under their own brands.
The model can be sticky. A device can take 3 to 5 years to develop and win regulatory approval, so customers do not switch key suppliers lightly. Integer often becomes deeply tied to a product before it launches, and in some cases can be a sole-source supplier for an important component.
The company also buys small businesses that add useful capabilities. In 2025 it bought Precision Coatings, BSI Parylene, and Biocoat assets, adding more coating technology and services. These coatings can make devices easier to use inside the body, such as helping catheters move through blood vessels.
Where it breaks is forecast control. Integer does not own the end market demand. If a customer's device sells slower than expected, or if an OEM changes order timing, Integer feels it quickly.
Where Integer shows up
Cardio & Vascular
This is the largest product line and includes guidewires, catheters, electrophysiology tools, neurovascular products, and parts for structural heart devices. It has historically been a strong growth driver, aided by acquisitions.
Electrophysiology and PFA catheters
Electrophysiology, including pulsed field ablation, has been a major growth idea. It is also a current problem area, since recent customer forecast cuts hit the 2026 standalone outlook.
Cardiac Rhythm Management
Integer supplies components used in devices that manage heart rhythm. This is a steadier market, but it is not the main source of upside today.
Neuromodulation
Integer makes components and complete devices for customers that use electrical stimulation to treat nerve conditions. Emerging PMA customers generated about $125 million of 2024 sales.
Coatings and surface technologies
Recent acquisitions expanded Integer's coating services, including hydrophilic, parylene, and other surface treatments. These capabilities help make the company more useful to OEMs earlier in product design.
Other Markets
Other Markets is shrinking by design. Sales fell 27% in 2025 as Integer continued its planned exit from the Portable Medical product line.
One segment, three product lines
Integer reports as one business segment, but it gives sales by product line. The mix shown uses fiscal 2025 sales from the 2025 Form 10-K, so it does not yet reflect the full 2026 electrophysiology slowdown.
What could go wrong
Merger failure or delay
High impact · Medium oddsThe definitive agreement with KKR is subject to shareholder and regulatory approvals. If antitrust concerns or other hurdles delay or block the deal, the stock will likely lose its M&A premium and trade lower on fundamental weakness.
Electrophysiology weakness lasts longer
High impact · Medium oddsIf the KKR deal fails, standalone results will matter again. Management previously noted that customers lowered second-half 2026 forecasts for a few electrophysiology products. A prolonged slowdown would hurt the 2027 recovery story.
OEM order timing stays lumpy
Medium impact · High oddsInteger depends on customer build plans. OEMs can pull orders forward, push them out, or lower forecasts as their own inventory changes. That can make a good quarter look stronger than demand really is, or a weak quarter look worse.
In one breath
What does Integer Holdings do?
Integer builds medical device components and finished devices for medtech OEMs. Its products show up in areas like cardio and vascular procedures, cardiac rhythm management, neuromodulation, and electrophysiology.
Is Integer being acquired?
Yes. On August 2, 2026, the company entered into a definitive agreement to be acquired by investment funds managed by KKR for $127 per share in cash.
What is the biggest issue for ITGR stock right now?
The biggest issue is closing the KKR transaction. If the merger fails due to regulatory or shareholder hurdles, the stock will fall back to trading on its standalone fundamentals, which were recently pressured by guidance cuts.
